30-day average of 11 articles · scale −100 to +100
Across 11 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Eli Lilly and Company news is Bullish (+54)
on a scale from −100 to +100.
That is down 6 points from the previous 30 days (+60).
🚀 Eli Lilly stock surged 3% to a record high after China approved orforglipron (Foundayo).
🏆 Foundayo approval positions Lilly ahead of Novo Nordisk for oral GLP-1 clearance in China.
Bullish +75
Eli Lilly (LLY) Stock Climbs as China Approves First GLP-1 Weight-Loss Pill
AI-generated analysis
Key insights
🚀 Eli Lilly stock climbed nearly 3% to a record high after China approved orforglipron (Foundayo) as the nation's first GLP-1 weight-loss pill.
🏆 Foundayo approval positions Lilly ahead of Novo Nordisk, which is still awaiting clearance for its oral Wegovy in China.
💊 The new oral therapy offers a once-daily, non-injection alternative that appeals to patients reluctant to use injections.
📈 J.P. Morgan forecasts China's GLP-1 weight-management market could reach $4.5 billion annually within five to seven years.
🇨🇳 China's obese population is projected to top 65% by 2030, creating a massive growth opportunity for Foundayo.
💰 Lilly reported strong third-quarter revenue of $24.4 billion, up 39%, driven by Mounjaro and Zepbound sales.
🌍 Foundayo is already generating $184 million in Q3 revenue globally, with total lifetime revenue reaching $281 million since launch.
⚔️ Foundayo will compete against Lilly's own weekly injection as well as injectables from Novo Nordisk, Pfizer, and Innovent Biologics.
📅 More GLP-1 pill competitors are entering the Chinese market, including applications from Jiangsu Hengrui Pharmaceuticals and Huadong Medicine.
📈 Bullish signals
🚀Eli Lilly stock hit a record high in premarket trading after China approved orforglipron (Foundayo) as the country's first GLP-1 weight-loss pill.
🏆Foundayo approval places Lilly ahead of competitor Novo Nordisk, which is still waiting for its oral Wegovy to be cleared in China.
💊The new oral therapy addresses patient preferences for non-injection treatments, potentially expanding the addressable market beyond current injectable users.
📈Analyst J.P. Morgan forecasts annual GLP-1 weight-management sales in China could reach $4.5 billion within five to seven years.
🇨China's obese population is projected to exceed 65% by 2030, providing a massive growth opportunity for Foundayo.
💰Lilly reported robust third-quarter revenue of $24.4 billion, a 39% increase driven by Mounjaro and Zepbound sales.
🌍Foundayo has generated $184 million in Q3 revenue globally, with total lifetime revenue reaching $281 million since its April FDA approval.
Article
Eli Lilly (LLY) shares surged nearly 3% in premarket trading after China's National Medical Products Administration approved orforglipron, sold as Foundayo, as the country's first GLP-1 weight-loss pill. This regulatory milestone establishes Lilly as a market leader ahead of competitor Novo Nordisk, whose oral Wegovy remains pending approval in China. The approval marks a significant expansion for Lilly into the world's second-largest pharmaceutical market with an oral therapy that addresses patient preferences for non-injection treatments.
Foundayo is designed to be taken once daily without food or water restrictions, offering a convenient alternative to injections and potentially expanding the addressable market beyond current injectable users. While Foundayo will compete with Lilly's own weekly GLP-1 injection as well as rival injectables from Novo Nordisk, Pfizer, and Innovent Biologics, the oral format is expected to capture significant demand given that oral therapies already account for roughly one-third of obesity prescriptions in the U.S.
Analyst J.P. Morgan forecasts that annual GLP-1 weight-management sales in China could reach 30 billion yuan ($4.5 billion) within five to seven years, driven by a growing obese population projected to exceed 65% by 2030. Lilly's broader financial performance remains robust, with total third-quarter revenue rising 39% to $24.4 billion, primarily driven by Mounjaro and Zepbound sales. The company has not yet disclosed specific pricing or launch timelines for Foundayo in China, though early availability on JD.com suggests imminent market entry.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Drug approvalMarket expansionAI-generated analysis
Eli Lilly (LLY) shares surged nearly 3% in premarket trading after China's National Medical Products Administration approved orforglipron, sold as Foundayo, as the country's first GLP-1 weight-loss pill. This regulatory milestone establishes Lilly as a market leader ahead of competitor Novo Nordisk, whose oral Wegovy remains pending approval in China. The approval marks a significant expansion for Lilly into the world's second-largest pharmaceutical market with an oral therapy that addresses patient preferences for non-injection treatments.
Foundayo is designed to be taken once daily without food or water restrictions, offering a convenient alternative to injections and potentially expanding the addressable market beyond current injectable users. While Foundayo will compete with Lilly's own weekly GLP-1 injection as well as rival injectables from Novo Nordisk, Pfizer, and Innovent Biologics, the oral format is expected to capture significant demand given that oral therapies already account for roughly one-third of obesity prescriptions in the U.S.
Analyst J.P. Morgan forecasts that annual GLP-1 weight-management sales in China could reach 30 billion yuan ($4.5 billion) within five to seven years, driven by a growing obese population projected to exceed 65% by 2030. Lilly's broader financial performance remains robust, with total third-quarter revenue rising 39% to $24.4 billion, primarily driven by Mounjaro and Zepbound sales. The company has not yet disclosed specific pricing or launch timelines for Foundayo in China, though early availability on JD.com suggests imminent market entry.
🚀 Eli Lilly stock surged 3% to a record high after China approved orforglipron (Foundayo).
🏆 Foundayo approval positions Lilly ahead of Novo Nordisk for oral GLP-1 clearance in China.
💊 The new therapy offers a once-daily, non-injection alternative appealing to patients avoiding needles.
💰 Strong Q3 revenue of $24.4 billion was driven by Mounjaro and Zepbound sales growth.
🌍 Foundayo generated $184 million in Q3 global revenue with $281 million lifetime revenue since launch.
🚀 Eli Lilly stock climbed nearly 3% to a record high after China approved orforglipron (Foundayo) as the nation's first GLP-1 weight-loss pill.
🏆 Foundayo approval positions Lilly ahead of Novo Nordisk, which is still awaiting clearance for its oral Wegovy in China.
💊 The new oral therapy offers a once-daily, non-injection alternative that appeals to patients reluctant to use injections.
📈 J.P. Morgan forecasts China's GLP-1 weight-management market could reach $4.5 billion annually within five to seven years.
🇨🇳 China's obese population is projected to top 65% by 2030, creating a massive growth opportunity for Foundayo.
💰 Lilly reported strong third-quarter revenue of $24.4 billion, up 39%, driven by Mounjaro and Zepbound sales.
🌍 Foundayo is already generating $184 million in Q3 revenue globally, with total lifetime revenue reaching $281 million since launch.
⚔️ Foundayo will compete against Lilly's own weekly injection as well as injectables from Novo Nordisk, Pfizer, and Innovent Biologics.
📅 More GLP-1 pill competitors are entering the Chinese market, including applications from Jiangsu Hengrui Pharmaceuticals and Huadong Medicine.
Bullish Signals
Eli Lilly stock hit record high after China approved orforglipron.
Foundayo approval places Lilly ahead of Novo Nordisk in China.
Oral therapy expands market beyond injectable users with patient preference.
Analysts forecast $4.5 billion GLP-1 sales in China within 7 years.
Q3 revenue reached $24.4 billion, up 39% on Mounjaro/Zepbound.
Bullish Signals
Eli Lilly stock hit a record high in premarket trading after China approved orforglipron (Foundayo) as the country's first GLP-1 weight-loss pill.
Foundayo approval places Lilly ahead of competitor Novo Nordisk, which is still waiting for its oral Wegovy to be cleared in China.
The new oral therapy addresses patient preferences for non-injection treatments, potentially expanding the addressable market beyond current injectable users.
Analyst J.P. Morgan forecasts annual GLP-1 weight-management sales in China could reach $4.5 billion within five to seven years.
China's obese population is projected to exceed 65% by 2030, providing a massive growth opportunity for Foundayo.
Lilly reported robust third-quarter revenue of $24.4 billion, a 39% increase driven by Mounjaro and Zepbound sales.
Foundayo has generated $184 million in Q3 revenue globally, with total lifetime revenue reaching $281 million since its April FDA approval.
Eli Lilly and Company (LLY) shares surged 4.50% to $1,414.93 following the announcement of positive Phase 3 clinical results for its investigational drug Foundayo (orforglipron). The ATTAIN-OSA program evaluated the treatment in adults with moderate-to-severe obstructive sleep apnea and obesity, demonstrating significant efficacy in reducing breathing interruptions and supporting weight loss.
The study met its primary endpoint by significantly lowering the apnea-hypopnea index after 52 weeks. Among participants not using positive airway pressure (PAP) therapy, Foundayo reduced sleep apnea events by 43.8%, while those using PAP therapy saw a 27.5% decline. Additionally, the treatment delivered average weight reductions exceeding 11% across both patient groups, alongside improvements in systolic blood pressure and inflammatory markers.
Eli Lilly plans to submit an application for FDA approval for Foundayo's use in obstructive sleep apnea by December 2026. The company presented findings at the American Heart Association Scientific Sessions 2026 and published them in JAMA, aiming to expand its cardiometabolic portfolio beyond existing obesity treatments like Zepbound. While gastrointestinal side effects were noted, the positive clinical data strengthens Lilly's position in treating obesity-related health conditions.
📈 LLY stock rose 4.50% after positive Phase 3 Foundayo sleep apnea results.
🩺 ATTAIN-OSA program met primary endpoint, reducing apnea events by 43.8%.
⚖️ Treatment achieved average weight loss of 11.5% and improved blood pressure.
⚠️ GI symptoms were most common adverse events with 12.2% discontinuation rates.
🗓️ LLY plans FDA approval submission for Foundayo by December 2026.
📈 LLY stock jumped 4.50% to $1,414.93 on Monday following the release of positive Phase 3 clinical results for Foundayo.
🩺 The ATTAIN-OSA program met its primary endpoint by significantly reducing the apnea-hypopnea index in adults with moderate-to-severe obstructive sleep apnea.
⚖️ Foundayo reduced sleep apnea events by 43.8% among participants without PAP therapy and 27.5% among those using PAP therapy after 52 weeks.
📉 The treatment delivered average weight reductions of 11.5% for patients without PAP therapy and 11.2% for those with PAP therapy.
🏥 Participants showed improvements in systolic blood pressure and inflammatory markers, addressing key cardiovascular risk factors associated with obesity.
🗓️ Eli Lilly plans to submit an application for FDA approval for Foundayo's sleep apnea indication by December 2026.
📊 Findings were presented at the American Heart Association Scientific Sessions 2026 and published in the journal JAMA.
⚠️ Gastrointestinal symptoms such as nausea, diarrhea, and vomiting were identified as the most common adverse events during the trials.
📉 Discontinuation rates due to adverse events were 12.2% for non-PAP users and 6.8% for PAP users receiving Foundayo versus placebo.
💼 The positive results support Eli Lilly's strategy to expand its cardiometabolic portfolio beyond current obesity treatments like Zepbound.
Bullish Signals
Stock rallied 4.50% on Foundayo Phase 3 success.
Drug cut sleep apnea events by 43.8% in non-PAP users.
Trials showed BP and inflammation improvements for cardiometabolic value.
FDA submission planned by Dec 2026 to expand indications.
Risk Factors
GI adverse events caused 12.2% discontinuation in non-PAP users.
Side effects led to 6.8% discontinuation for PAP therapy users.
Bullish Signals
LLY stock rallied 4.50% to $1,414.93 driven by positive Phase 3 data showing Foundayo met its primary endpoint for reducing sleep apnea severity.
The drug reduced sleep apnea events by 43.8% in non-PAP users and 27.5% in PAP users, validating efficacy across different treatment populations.
Foundayo delivered average weight loss exceeding 11% across both patient groups, reinforcing its dual benefit for obesity and sleep apnea management.
Clinical trials demonstrated improvements in systolic blood pressure and inflammatory markers, expanding the drug's potential cardiometabolic value proposition.
Eli Lilly plans an FDA submission by December 2026 to expand Foundayo's approved indications, creating a new revenue stream within its portfolio.
Risk Factors
Gastrointestinal adverse events including nausea, diarrhea, and vomiting were common, leading to a 12.2% discontinuation rate among non-PAP users.
Discontinuation rates due to side effects reached 6.8% for patients using PAP therapy, compared to lower rates observed with placebo.
Drug pricingEarnings reportFinancial outlookAI-generated analysis
Eli Lilly (LLY) reported a 34% increase in U.S. revenue for the third quarter of 2026, driven primarily by surging volumes of its weight-loss drugs Mounjaro and Zepbound. Despite this volume growth, the company's net price per prescription in the U.S. declined by 10% during the same period. Management noted that while the balance between pricing power and sales volume remains a key metric to monitor, the overall revenue expansion was bolstered by approximately $900 million in milestone payments and adjustments to rebate estimates.
Global revenue for Eli Lilly reached $24.4 billion in the third quarter of 2026, representing a 38.6% year-over-year increase. The two blockbuster drugs, Mounjaro and Zepbound, accounted for over $16 billion of total revenue, supplying roughly $6 billion of the quarterly growth. Consequently, these two products constitute the vast majority of the company's financial performance, meaning any sustained shift in pricing or reimbursement rates will have a disproportionate impact on overall earnings.
Looking ahead to 2027, management expects commercial insurance coverage in the U.S. to remain stable while new access expands into Medicare and Medicaid markets. The company anticipates that lower net prices associated with these government programs will be offset by higher prescription volumes rather than representing an overall price cut. Additionally, the 2026 revenue forecast was raised to $91.5 billion at the midpoint, excluding about $2 billion in one-time items related to milestone payments and rebate adjustments.
Analysts are closely watching the upcoming fourth-quarter report expected in February 2027 to determine the specific magnitude of U.S. price declines versus volume growth. Management has stated its goal is to maintain a tighter pricing band for obesity drugs globally compared to other therapeutic categories. Investors will need to track whether the shift toward lower-paying government payers materially impacts margins or if volume expansion continues to drive top-line success.
📈 U.S. revenue surged 34% in Q3 2026 driven by Mounjaro and Zepbound volume.
💰 Net price per prescription fell 10% despite massive sales growth.
🌍 Global revenue hit $24.4B with weight-loss drugs contributing over $16B.
📅 Full-year 2026 forecast raised to $91.5B midpoint from $86B estimate.
🏥 Patient mix shift to Medicare/Medicaid expected in 2027 lowering net prices.
📈 Eli Lilly's U.S. revenue surged 34% in Q3 2026, reaching new highs driven by massive volume increases in Mounjaro and Zepbound sales.
💰 Despite the revenue boom, the net price per prescription for Lilly's U.S. sales fell 10% in the third quarter of 2026.
🌍 Global revenue hit $24.4 billion in Q3 2026, with Mounjaro and Zepbound contributing over $16 billion to the total.
📅 Management raised its full-year 2026 revenue forecast to $91.5 billion at the midpoint, up from the previous $86 billion estimate.
🏥 The company expects a shift in U.S. patient mix toward Medicare and Medicaid in 2027, which typically carries lower net prices per prescription.
💸 Approximately $900 million of Q3 revenue was generated by milestone payments and adjustments to rebate estimates across all markets.
📉 Management aims for a tighter pricing band for obesity drugs globally compared to other pharmaceutical categories.
🔍 Investors are advised to watch the February 2027 earnings report for specific data on Q4 U.S. price changes versus volume growth.
🚀 The two weight-loss drugs now account for the majority of Lilly's revenue, making them critical to the company's financial health.
Bullish Signals
U.S. revenue rose 34% YoY in Q3 2026.
Mounjaro/Zepbound generated over $16B in Q3 2026.
Raised full-year 2026 revenue forecast to $91.5B.
Secured ~$900M from milestones and rebates in Q3.
Risk Factors
Net price declined 10% in Q3 2026 due to pricing pressure.
Patient mix shift to Medicare/Medicaid expected in 2027.
Bullish Signals
Eli Lilly achieved a 34% year-over-year increase in U.S. revenue during the third quarter of 2026, demonstrating strong demand for its core products.
The company generated over $16 billion in revenue from Mounjaro and Zepbound combined in Q3 2026, highlighting the massive scale of its weight-loss franchise.
Management raised its full-year 2026 revenue forecast to $91.5 billion at the midpoint, reflecting confidence in continued growth despite pricing headwinds.
The company secured approximately $900 million in additional revenue from milestone payments and rebate adjustments during the third quarter of 2026.
Risk Factors
Eli Lilly's net price per prescription in the U.S. declined by 10% in the third quarter of 2026, indicating ongoing pricing pressure on its blockbuster drugs.
The company anticipates a shift in U.S. patient mix toward Medicare and Medicaid in 2027, which management acknowledges will bring lower net prices per prescription compared to commercial insurance.
Eli Lilly (LLY) has shifted its capital allocation strategy, marking a historic change where capital spending on factories and equipment exceeded research and development for the first time since at least 2011. Over the twelve months ended September 30, 2026, the company spent $19.0 billion on capital projects compared to $15.4 billion on R&D, a reversal after 59 consecutive quarters of higher research investment.
This strategic pivot is driven by management's confidence in sustained growth for its weight-loss and diabetes portfolio, specifically Mounjaro and Zepbound, which generated over $16 billion in revenue during the third quarter alone. To support this expansion, Eli Lilly has announced plans for new manufacturing sites, including a $6.5 billion facility in Houston and another in Richmond, Virginia, bringing the total number of new U.S. manufacturing sites since 2020 to ten.
Financially, the heavy investment impacted free cash flow dynamics in the third quarter, which fell to $4.16 billion from $6.03 billion a year prior due to increased capital outlays, though full-year free cash flow still grew to $11.7 billion. The company's net debt rose to $44.6 billion by September 2026, yet remains manageable at 3.9% of market value compared to the S&P 500 average of 19.1%, reflecting its strong balance sheet despite the aggressive expansion.
Analysts and investors are advised to monitor the ratio of capital spending to research spending in future quarterly reports, with the next update expected on a fourth-quarter call in January. While the shift away from pure R&D dominance raises questions about long-term pipeline depth, the immediate driver is the need to build capacity for blockbuster drugs that have propelled the stock's significant outperformance over the last five years.
🏭 Capital spending hit $19.0B, surpassing R&D for first time since 2011.
💊 Mounjaro and Zepbound drove over $16B Q3 revenue amid factory expansion.
📈 Ground broken on $6.5B Houston facility with nine more U.S. sites planned.
💰 Free cash flow fell to $4.16B due to heavy capital investment surge.
🚀 Stock rose 482% over five years, outperforming 57 of 60 sector peers.
🏭 Eli Lilly spent $19.0 billion on capital projects in the twelve months ended September 30, 2026, surpassing its $15.4 billion research and development spending for the first time since 2011.
💊 Mounjaro and Zepbound combined generated over $16 billion in revenue during the third quarter, driving the company's aggressive expansion into new manufacturing facilities.
📈 The company broke ground on a $6.5 billion facility in Houston and plans additional sites in Richmond, Virginia, as part of ten new U.S. manufacturing locations announced since 2020.
💰 Free cash flow dropped to $4.16 billion in the third quarter from $6.03 billion a year earlier due to the surge in capital spending on factories and equipment.
📉 Net debt increased to $44.6 billion by September 2026, but remains low relative to market value at 3.9%, significantly below the S&P 500 average of 19.1%.
🔭 Investors are urged to watch the capital-to-research spending ratio in upcoming reports, with the next financial update expected on a fourth-quarter call in January.
🚀 Over the five years to October 2026, Eli Lilly's stock rose 482%, outperforming 57 of the 60 other pharmaceutical companies in the sector.
Bullish Signals
Mounjaro/Zepbound revenue exceeded $16B in Q3.
Net debt is only 3.9% of market value.
Full-year free cash flow reached $11.7B.
Ten new U.S. manufacturing sites announced.
Risk Factors
Capex of $19B exceeded R&D of $15.4B, ending 59-quarter streak.
Free cash flow dropped to $4.16B in Q3 from $6.03B.
Net debt rose to $44.6B by Sep 2026.
Bullish Signals
Mounjaro and Zepbound combined generated more than $16 billion in revenue during the third quarter, demonstrating strong demand for its weight-loss and diabetes portfolio.
The company's net debt of $44.6 billion represents only 3.9% of its market value, a significantly healthier leverage ratio compared to the S&P 500 average of 19.1%.
Full-year free cash flow grew to $11.7 billion for the twelve months ended September 2026, indicating that overall cash generation remains robust despite heavy capital investment.
Eli Lilly has announced ten new U.S. manufacturing sites since 2020, signaling a clear and funded long-term growth strategy supported by management confidence.
Risk Factors
Capital spending of $19.0 billion exceeded research and development spending of $15.4 billion in the trailing twelve months, ending a streak of 59 quarters where R&D was the larger investment.
Free cash flow declined to $4.16 billion in the third quarter from $6.03 billion a year earlier due to the substantial increase in capital expenditures on new factories.
Net debt rose to $44.6 billion by September 2026, up from approximately $32.6 billion a year earlier, reflecting the cash outflow required for aggressive capacity expansion.
Eli Lilly (LLY) reported a robust third quarter with worldwide revenue rising 39% to $24.4 billion, driven primarily by its obesity drug portfolio. The company highlighted that increased market access through lower realized prices is successfully expanding volume, with global sales volume up 53% despite a 15% decline in average pricing per unit. This strategy proved effective as Zepbound sales surged 49% to $5.35 billion and Mounjaro revenue jumped 65% to $10.72 billion.
Lilly's stock price rallied 7.5% to hit a record high, adding approximately $80 billion to its market capitalization as investors reacted positively to the company's revised full-year sales guidance of $91-92 billion. This represents a significant upward revision from the initial projection, reflecting confidence in the scalability of their weight-loss therapies even as pricing power faces headwinds from insurance negotiations and government pilots like the new Medicare program offering drugs for $50/month.
The article outlines Lilly's strategic pivot where sacrificing per-unit margins to capture a much larger addressable market is yielding substantial financial returns. Management is also expanding its pipeline with oral therapies like Foundayo and next-generation injectables such as retatrutide, while simultaneously investing heavily in manufacturing capacity in Virginia and Texas to meet surging demand. Analysts view this volume-over-price dynamic as a sustainable growth model that could redefine the economics of the obesity treatment sector.
📈 Q3 revenue hit $24.4B driven by 53% volume growth despite 15% price declines.
💊 Zepbound sales surged 49% to $5.35B, raising full-year guidance by $5.5B.
🚀 Shares gained 7.5% to a record high as Foundayo and retatrutide advance.
🏭 Manufacturing expanded in Virginia and Texas to resolve supply constraints for blockbusters.
⚠️ Competition from Novo Nordisk and pricing pressure pose risks to the growth model.
📈 Eli Lilly reported third-quarter worldwide revenue of $24.4 billion, a 39% year-over-year increase driven by massive volume growth.
💊 Zepbound sales reached $5.35 billion in the quarter, representing a 49% increase compared to the same period last year.
🩸 Mounjaro revenue hit $10.72 billion, surging 65% as the company solidifies its position in the diabetes and obesity markets.
📉 Realized prices for Lilly's drugs declined by 15% globally, yet this was more than offset by a 53% rise in global sales volume.
🚀 The company raised its full-year sales guidance to between $91 billion and $92 billion, adding $5.5 billion to initial projections.
📈 Shares surged 7.5% on Thursday to hit a record high of $1,408.34, increasing the company's market value by over $80 billion.
💊 Lilly introduced Foundayo, an oral obesity therapy, and is advancing retatrutide, a next-generation injectable showing 24% weight reduction in midstage testing.
🏭 The pharmaceutical giant is expanding manufacturing operations in Virginia and Texas to address supply constraints for its blockbuster drugs.
🤝 A new Medicare pilot program enrolled over 500,000 patients accessing obesity drugs for $50 a month, validating the volume-over-price strategy.
⚠️ Competition from rivals like Novo Nordisk and potential government pricing pressure remain key risks to the company's high-margin growth model.
Bullish Signals
Sales guidance raised to $91-92B, boosting investor confidence.
Global weight-loss volume up 53% despite lower prices.
Zepbound revenue hit $5.35B with 49% YoY growth.
Stock surged 7.5% to record high, adding $80B cap.
Realized prices fell 15% globally, trading margin for volume.
Rivals like Novo Nordisk and insurer leverage threaten margins.
Earnings risk if volume growth fails to offset price drops.
Bullish Signals
Eli Lilly increased its full-year sales guidance to $91-92 billion, a $5.5 billion upward revision that reflects strong investor confidence in the scalability of its obesity portfolio.
Global sales volume for weight-loss drugs rose 53% while realized prices fell 15%, demonstrating that the company successfully captured a much larger market share without sacrificing total revenue.
Zepbound generated $5.35 billion in Q3 revenue (49% YoY growth) and Mounjaro generated $10.72 billion (65% YoY growth), proving the dual-drug strategy is highly effective.
The stock price surged 7.5% to a record high, adding approximately $80 billion to market cap as investors priced in the transition from scarcity-driven exclusivity to mass-market accessibility.
Lilly's volume growth of 53% globally more than compensated for lower per-unit pricing, validating the strategic shift toward affordable access which expands the total addressable market.
The company is diversifying its obesity offerings with Foundayo (oral) and retatrutide (injectable), reducing reliance on a single delivery method and broadening patient eligibility.
Risk Factors
Realized prices for Lilly's drugs declined by 15% globally, indicating that the company is trading margin per unit to gain volume, which could pressure future profit margins if volume growth slows.
Intense competition from rivals like Novo Nordisk and increasing government/insurer leverage to drive down drug pricing pose a long-term threat to the high-margin business model.
The success of the lower-price strategy is contingent on continued rapid volume expansion; if sales volume fails to keep pace with falling prices, overall earnings could stagnate or decline.
Drug approvalEarnings reportGuidance raisedAI-generated analysis
Eli Lilly (LLY) shares surged nearly 7% to a record high of $1,373.70 after the company raised its 2026 revenue forecast to between $91 billion and $92 billion. This guidance represents a midpoint increase of approximately $10 billion compared to February estimates, driven primarily by unexpected positive outcomes in two key variables: the rapid ramp-up of the Medicare GLP-1 Bridge program and increased cash payments from middle-income households abroad for weight-loss drugs.
The company reported strong third-quarter financials with revenue rising 39% year-over-year to $24.4 billion, beating analyst consensus by roughly $1.8 billion. Adjusted earnings per share of $7.48 also exceeded expectations, though GAAP EPS fell short due to significant one-time research charges totaling $4.57 per share. Management clarified that about $2 billion of the 2026 revenue guidance consists of non-recurring milestones and rebate adjustments that will not repeat in future years.
Looking ahead, the company faces a challenging environment for 2027 where net price headwinds are expected to offset volume growth, potentially requiring a lower revenue multiple. CEO David Ricks highlighted that while the current expansion is the largest new category in pharmaceutical history, the 'surprise factor' will diminish as variables become more predictable. Investors are closely watching the upcoming January earnings call for 2027 guidance to determine if volume can sustain growth despite anticipated price declines and the eventual shift of the Bridge program to Medicare Part D.
Analysts remain bullish on the long-term runway driven by new products like Foundayo for type 2 diabetes and investigational retatrutide, which showed superior efficacy in recent trials. However, the stock currently trades at a premium valuation of roughly 31x next-year earnings compared to Novo Nordisk's 12x multiple. The primary risk identified is the sustainability of growth if the one-time revenue boosts fade and volume fails to outpace price reductions in the coming year.
📈 LLY stock hit record $1,373.70 after raising 2026 sales forecast to $92 billion.
💰 Q3 revenue surged 39% to $24.4B, beating estimates by $1.8 billion.
⚠️ Management warns $2B of 2026 revenue is non-recurring and will not repeat.
📉 CFO expects 2027 net price headwinds to offset volume growth.
💊 Retatrutide showed superior weight loss vs Novo Nordisk's Ozempic in trials.
📈 Eli Lilly stock jumped nearly 7% to a record $1,373.70 after lifting its 2026 sales forecast to as much as $92 billion.
💰 Q3 revenue surged 39% to $24.4 billion, beating consensus estimates by approximately $1.8 billion.
🚀 The Medicare GLP-1 Bridge program and international cash-pay adoption added roughly $10 billion to the 2026 forecast unexpectedly.
⚠️ Management warned that about $2 billion of 2026 revenue is non-recurring and will not repeat in future years.
📉 CFO Lucas Montarce expects net price headwinds in 2027 to offset volume growth, making the $103 billion Street estimate difficult.
💊 Investigational retatrutide demonstrated superior weight loss and A1C reduction compared to Novo Nordisk's Ozempic in recent trials.
🏥 Foundayo for type 2 diabetes is expected to receive a U.S. regulatory decision in the fourth quarter.
📊 The stock trades at a premium 31x NTM P/E multiple, significantly higher than competitor Novo Nordisk's 12x multiple.
🔮 CEO David Ricks noted that as variables become predictable, future revenue guidance raises may become smaller.
🗓️ Investors await the January earnings call for 2027 guidance to see if volume can absorb the lost one-time revenue.
Bullish Signals
Raised 2026 revenue forecast to $91-$92 billion.
Q3 revenue grew 39% YoY to $24.4B.
Adjusted EPS of $7.48 beat estimates.
GLP-1 expansion drove strong performance.
Retatrutide showed double Novo Nordisk weight loss.
Risk Factors
$2B 2026 revenue includes non-recurring milestones.
CFO expects 2027 price headwinds to offset volume.
Trades at 31x earnings vs Novo Nordisk's 12x.
Future guidance raises may become smaller.
Bullish Signals
Eli Lilly raised its 2026 revenue forecast to $91-$92 billion, a midpoint increase of roughly $10 billion over February estimates.
Q3 revenue grew 39% year-over-year to $24.4 billion, beating analyst consensus by approximately $1.8 billion.
Adjusted EPS of $7.48 exceeded the $6.35 estimate, driven by strong performance in the GLP-1 category expansion.
The Medicare GLP-1 Bridge program and international cash-pay adoption contributed roughly $10 billion to the 2026 forecast.
Investigational retatrutide showed superior clinical results with more than double the weight loss of Novo Nordisk's Ozempic.
Foundayo for type 2 diabetes is expected to receive a U.S. regulatory decision in the fourth quarter, adding new revenue streams.
Risk Factors
Approximately $2 billion of the 2026 revenue guidance consists of one-time milestones and rebate changes that management does not expect to recur.
CFO Lucas Montarce expects net price headwinds in 2027 to offset volume growth, making the Street's $103 billion revenue estimate challenging.
The stock trades at a premium valuation of roughly 31x next-year earnings compared to Novo Nordisk's 12x multiple, leaving room for compression if growth slows.
CEO David Ricks indicated that as the 'surprise factor' runs its course, future revenue guidance raises may become smaller and more predictable.
Drug approvalEarnings reportGuidance raisedAI-generated analysis
Eli Lilly (LLY) is set to report third-quarter earnings on October 29, following a streak of five consecutive EPS beats and a stock price surge of nearly 20% year-to-date. The company's financial performance remains heavily anchored by its blockbuster tirzepatide franchise, with Mounjaro sales climbing 91% to $9.94 billion and Zepbound growing 46% to $4.93 billion in the prior quarter.
Despite strong revenue growth of 47.7% to $22.97 billion last quarter, Wall Street consensus estimates for Q3 EPS have dropped significantly from $9.87 to $6.67 due to acquired IPR&D charges. Management has raised full-year revenue guidance twice this year to a range of $85 billion to $87 billion, though the consensus already sits higher at $88.68 billion.
Three key catalysts are driving investor attention ahead of the earnings release: potential for another guidance raise driven by international demand, volume growth offsetting recent U.S. price declines, and progress on next-generation weight loss drugs like retatrutide. While Lilly claims Zepbound outperforms Novo Nordisk's Wegovy HD in indirect comparisons, pricing pressure from competitors remains a noted margin risk.
📈 Lilly beats EPS for five consecutive quarters through October 29.
💰 Q2 revenue surged 47.7% driven by Mounjaro and Zepbound growth.
🚀 Management raised full-year revenue guidance to $85B-$87B range.
🌍 International tirzepatide demand grew 172% after China NRDL inclusion.
💊 Foundayo generated $98M in launch quarter with volumes doubling.
📈 Eli Lilly reports Q3 earnings on October 29 after five consecutive quarters of beating EPS estimates.
💰 Q2 revenue surged 47.7% to $22.97 billion, with Mounjaro sales up 91% and Zepbound up 46%.
📉 Q3 EPS estimates fell from $9.87 to $6.67 due to acquired IPR&D charges impacting non-GAAP metrics.
🚀 Management raised full-year revenue guidance twice this year to a range of $85 billion to $87 billion.
🌍 International tirzepatide demand grew 172% in Q2 following China's NRDL inclusion, supporting potential further guidance raises.
📉 U.S. pricing for Mounjaro fell 9% excluding rebates, but management expects volume growth to offset the impact.
💊 Foundayo generated $98 million in its launch quarter with volumes almost doubling from a month earlier.
🔬 CEO David Ricks stated Lilly has all clinical data needed for retatrutide BLA filing expected in Q1 2027.
⚖️ Lilly's Zepbound outperformed Novo Nordisk's Wegovy HD in weight loss, though competitor pricing poses margin risks.
📉 Shares gained 19.07% year-to-date despite recent downward revisions to Q3 EPS estimates by analysts.
Drug pricingEarnings reportGuidance raisedAI-generated analysis
Eli Lilly and Company (NYSE:LLY) has delivered exceptional growth, with its stock returning over 55% in the past year compared to a 14% gain for the S&P 500. This premium valuation is driven by substantial expectations for future profitability, particularly from its diabetes and obesity treatments, Mounjaro and Zepbound, which are driving extraordinary sales momentum.
Second-quarter results provided strong support for these growth expectations, with revenue surging 48% year over year to $23.0 billion, fueled by a 60% increase in volume. Non-GAAP earnings per share rose 33% to $8.38, while Mounjaro generated $9.9 billion and Zepbound contributed $4.9 billion in quarterly revenue. Together, these two medicines accounted for a significant portion of the company's total revenue.
Profitability improvements further bolstered investor confidence, with non-GAAP gross margins expanding to 86.3%. To sustain this momentum, Lilly committed an additional $4.5 billion to expand manufacturing capacity in Indiana. The company is also advancing its pipeline, including oral GLP-1 medicine Foundayo and investigational treatment retatrutide, which showed positive Phase 3 results.
However, the article highlights key risks regarding the sustainability of this growth. While volume growth has compensated for declining realized prices domestically, international revenue faced significant pricing pressure due to factors like Mounjaro's inclusion on China's National Reimbursement Drug List. Management raised underlying full-year non-GAAP EPS outlook by $2.78 at the midpoint, but acquisition-related R&D charges of $3.03 per share offset this in published guidance.
Pennsylvania Attorney General Dave Sunday has filed a lawsuit against Eli Lilly and Company, along with Novo Nordisk Inc., Sanofi-Aventis US LLC, and major pharmacy benefit managers including CVS Caremark. The state alleges that these entities conspired to artificially inflate insulin prices, driving costs to more than ten times their previous levels while leaving patients with significantly higher out-of-pocket bills.
The legal filing, made in the Commonwealth Court under Pennsylvania's consumer protection statute, claims unjust enrichment and civil conspiracy. It argues that the companies coordinated market behavior rather than competing on price, directly harming the estimated 1.3 million Pennsylvanians living with diabetes and the broader state healthcare system which faces an annual cost of $16.4 billion related to diagnosed diabetes.
Beyond seeking monetary damages and restitution for harmed residents, the lawsuit requests injunctive relief to restructure insulin pricing mechanisms and restore fair market levels. The state aims to broaden patient choice and hold large pharmaceutical companies accountable for prioritizing profits over public access to essential life-saving medication.
📜 PA AG sues Eli Lilly for alleged insulin price coordination with rivals.
⚖️ State accuses Eli Lilly of civil conspiracy driving prices 10x higher.
👥 Lawsuit affects 1.3M Pennsylvanians with diabetes facing higher bills.
💰 Alleged pricing scheme costs PA state $16.4B annually in diabetes care.
🛑 Filing seeks injunctive relief to lower Eli Lilly insulin prices.
📜 Pennsylvania Attorney General Dave Sunday filed a lawsuit against Eli Lilly, Novo Nordisk, Sanofi-Aventis, and pharmacy benefit managers including CVS Caremark alleging market coordination.
⚖️ The state accuses the defendants of civil conspiracy and unjust enrichment that drove insulin prices to over 10 times their prior levels.
👥 The lawsuit impacts approximately 1.3 million Pennsylvanians with diabetes and 3.5 million with prediabetes who face higher pharmacy bills.
💰 Pennsylvania estimates diagnosed diabetes costs the state $16.4 billion annually, exacerbated by alleged pricing decisions from a small group of major companies.
🛑 The filing seeks injunctive relief to change insulin pricing structures and push prices back toward fair market levels.
⚠️ Eli Lilly faces claims that it participated in a scheme to artificially inflate pricing to maximize company profits at the expense of patient access.
Risk Factors
Named in PA lawsuit alleging insulin price conspiracy.
State claims coordinated conduct raised prices 10x.
Lawsuit alleges prioritizing profits over patient access.
PA seeks injunctive relief to change pricing.
Risk Factors
Eli Lilly is named in a Pennsylvania lawsuit alleging it conspired with other manufacturers and pharmacy benefit managers to significantly increase insulin prices.
The state claims LLY participated in coordinated market conduct rather than competing on price, resulting in patients paying more than ten times prior levels.
The lawsuit alleges that LLY prioritized profits over public access to affordable life-saving medication, potentially harming 1.3 million Pennsylvanians with diabetes.
Pennsylvania seeks injunctive relief against LLY and others to change how insulin pricing is structured and restore fair market levels.
Company updateEarnings reportProduction ramp-upAI-generated analysis
Eli Lilly (LLY) has experienced significant stock appreciation driven primarily by the commercial success of its diabetes and obesity drugs, Zepbound and Mounjaro. By mid-2026, these two products accounted for approximately 65% of the company's quarterly revenue, generating $14.9 billion in the quarter ended June 2026. This concentration represents a major shift in the company's financial profile, with growth largely fueled by increased prescription volumes rather than price hikes.
The company has successfully navigated production constraints that previously limited its ability to meet demand. Executives highlighted supply expansion as a top priority starting in late 2024, and subsequent filings confirmed that manufacturing capacity caught up with market needs. Revenue growth accelerated from the initial post-pandemic levels to over 45% in early 2025 before moderating slightly as the company managed its inventory and production ramp-up.
Financial metrics show strong profitability alongside revenue expansion. Operating margins improved significantly, reaching 45.1% by mid-2025 from roughly 38.8% a year prior. While U.S. prices faced downward pressure of 9% in the most recent quarter, volume growth offset this decline, resulting in overall revenue increases of over 33%. The company continues to expand its manufacturing footprint with new commercial sites coming online in Ireland.
📈 Zepbound/Mounjaro revenue hit $14.9B, representing 65% of total sales.
🏭 Production capacity constraints are resolved to meet rising demand.
💰 Operating margins expanded to 45.1%, up from 38.8% last year.
📉 U.S. prices fell 9% excluding rebate and discount changes.
💉 U.S. revenue grew 33% driven by higher prescription volumes.
📈 Zepbound and Mounjaro generated $14.9 billion in revenue for the quarter ended June 2026, representing approximately 65% of total quarterly sales.
🏭 Management confirmed that production capacity constraints have been resolved, allowing the company to meet rising demand for its blockbuster drugs.
💰 Operating margins expanded significantly to 45.1% in the quarter ended June 2025, up from 38.8% in September 2024.
📊 Revenue growth moderated slightly to 47.7% year-over-year in the June 2026 quarter compared to 55.5% in the March quarter.
💉 U.S. revenue grew 33% in the June 2026 quarter, driven primarily by higher prescription volumes rather than price increases.
🌍 The company launched its first batch of commercial material at a new manufacturing site in Limerick, Ireland.
📅 Combined sales of Zepbound and Mounjaro increased by $6.3 billion from the June 2025 quarter to the June 2026 quarter.
📉 U.S. prices for the company's core drugs fell 9% in the June 2026 quarter when excluding changes in rebate and discount estimates.
Bullish Signals
Zepbound/Mounjaro revenue hit $14.9B, ~65% of total sales.
Manufacturing capacity expanded to resolve prior supply constraints.
Operating margins improved to 45.1% in Q2 2025.
U.S. revenue grew 33% YoY driven by core drugs.
Risk Factors
Revenue growth slowed to 47.7% YoY in June 2026.
U.S. core drug prices fell 9%, pressuring margins.
Bullish Signals
Zepbound and Mounjaro generated $14.9 billion in revenue for the quarter ended June 2026, accounting for roughly 65% of total quarterly sales.
The company successfully expanded manufacturing capacity to meet demand, resolving previous supply constraints that limited growth potential.
Operating margins improved substantially to 45.1% in the quarter ended June 2025, reflecting strong pricing power and cost management.
Revenue grew 33% year-over-year in the U.S. for the June 2026 quarter, driven by increased prescription volumes of core drugs.
Risk Factors
Revenue growth rate slowed to 47.7% year-over-year in the June 2026 quarter from a higher 55.5% expansion in the March quarter.
U.S. prices for core drugs fell 9% in the June 2026 quarter, indicating potential margin pressure if volume growth does not fully offset price declines.
As of October 16, 2026, Eli Lilly and Company (LLY) trades at $1,251.61 with a market capitalization of $1.12 trillion. The stock exhibits bullish technical momentum, trading above its 50-day simple moving average of $1,179.04 and showing an RSI of 68, which indicates strength without being overbought. Wall Street analysts maintain a consensus price target of $1,385.00, representing a potential upside of approximately 10.7% from current levels.
Eli Lilly has demonstrated a strong track record of beating earnings estimates, having exceeded analyst EPS expectations in six of its last seven reported quarters. The most recent report on August 5, 2026, saw actual EPS come in 27.36% above the consensus estimate, driving the stock up 1.89% in the first trading session. Analyst sentiment remains overwhelmingly positive, with 25 out of 30 analysts rating the stock as a Buy or Strong Buy.
Insider activity shows mixed signals but is largely attributed to corporate restructuring rather than management confidence issues. Lilly Endowment, Inc., which accounts for 99% of total insider selling, has been reducing its stake, while open-market sales by other insiders totaled $3.9 billion over the last 18 months compared to only $4.5 million in purchases. Long-term performance data highlights a decade-long growth trajectory where a $10,000 investment in October 2016 would be worth approximately $186,239 today with dividends reinvested.
📈 LLY trades at $1,251.61 with bullish RSI of 68 and $1.12T market cap.
🎯 Wall Street consensus target is $1,385.00, implying ~10.7% upside potential.
💰 EPS beat expectations by 27.36% in the latest quarter after 6/7 wins.
Earnings reportNew drug indicationAI-generated analysis
Eli Lilly and Co. (LLY) stock traded at EUR 1,093.80 on October 15, 2026, positioning it just 1.19 percent below its 52-week high of EUR 1,107.00. The company is approaching a critical earnings update scheduled for October 29, 2026, which investors view as the primary test for sustaining its rapid sales growth trajectory.
Financial performance remains robust with second-quarter 2026 revenue reaching USD 22.97 billion, representing a significant 47.70 percent year-over-year increase. Analysts and market watchers are closely monitoring whether this momentum can be maintained in the upcoming quarterly report, which will serve as a key benchmark against the established earnings-per-share guidance of USD 35.50 to USD 36.50.
Recent corporate developments highlight continued innovation and expansion in the pharmaceutical pipeline. Notable updates include an expanded indication for Jaypirca listed on October 2, 2026, and new Phase 3b data released on October 9, 2026, covering Taltz and Zepbound. Additionally, the company outlined 21 dermatology presentations for Fall Clinical 2026, signaling ongoing strategic focus in specific therapeutic areas.
📈 LLY trades at EUR 1,093.80, just 1.19% below its 52-week high.
💰 Q2 2026 revenue surged 47.70% to USD 22.97 billion.
📅 Earnings report scheduled for October 29, 2026 at 10:00 a.m. EDT.
💊 Jaypirca received expanded regulatory approval on October 2, 2026.
🔬 Phase 3b data released for Taltz and Zepbound on October 9, 2026.
📈 Eli Lilly stock is trading at EUR 1,093.80, sitting just 1.19 percent below its 52-week high of EUR 1,107.00.
💰 Second-quarter 2026 revenue surged to USD 22.97 billion, marking a 47.70 percent increase from the prior year.
📅 The company is set to report earnings on October 29, 2026, at 10:00 a.m. EDT to validate sustained growth.
💊 Eli Lilly received regulatory approval for an expanded indication for its drug Jaypirca on October 2, 2026.
🔬 New Phase 3b clinical data was released on October 9, 2026, covering the drugs Taltz and Zepbound.
🧴 The company announced 21 dermatology presentations for Fall Clinical 2026 to showcase pipeline progress.
🎯 Analysts are watching closely to see if revenue momentum matches the high Q2 performance in the upcoming report.
Bullish Signals
Q2 2026 revenue hit USD 22.97B, up 47.70% YoY.
Secured expanded Jaypirca indication on Oct 2, 2026.
Positive Phase 3b data released for Taltz and Zepbound.
Stock trades near yearly peak at EUR 1,093.80.
Risk Factors
Investors uncertain if rapid sales growth can sustain through Oct 29 earnings.
Stock trades below 52-week high with EUR 13.20 gap showing caution.
Bullish Signals
Eli Lilly reported exceptional second-quarter 2026 revenue of USD 22.97 billion, a 47.70 percent year-over-year increase that demonstrates strong sales growth.
The company successfully secured an expanded indication for Jaypirca on October 2, 2026, broadening its therapeutic reach and potential market opportunity.
Eli Lilly released positive new Phase 3b data for Taltz and Zepbound on October 9, 2026, reinforcing the efficacy of its key asset portfolio.
The stock is trading near its yearly peak at EUR 1,093.80, reflecting strong investor confidence ahead of the upcoming earnings report.
Risk Factors
Investors face uncertainty regarding whether the company can sustain its rapid sales growth momentum in the upcoming October 29 earnings report.
The stock is currently trading slightly below its 52-week high, leaving a gap of EUR 13.20 that could indicate cautious market sentiment ahead of results.
The article compares Bristol Myers Squibb and Eli Lilly & Co. (NYSE:LLY) as investment options, highlighting LLY's transformation into a growth powerhouse driven by its leadership in weight-loss and metabolic health treatments. While Bristol Myers Squibb is positioned as a value play with a recovering financial profile, the text argues that Eli Lilly offers superior future potential due to its dominant position in the GLP-1 market.
Eli Lilly reported significant financial expansion for fiscal year 2025, with revenue climbing approximately 45% to $65.2 billion and net income more than doubling to nearly $21 billion. The company achieved a net margin of roughly 32%, supported by a debt-to-equity ratio of 1.6x and free cash flow reaching $9.0 billion. These metrics underscore the strong profitability and operational efficiency of its core therapeutic areas.
Looking ahead, analysts project Eli Lilly's revenue to grow more than 30% in 2026, reaching an estimated $88.6 billion with net income approaching $31.4 billion. This growth is primarily fueled by the continued success of its GLP-1 drugs, Zepbound and Mounjaro, alongside anticipated contributions from the next-generation triple-agonist drug Retatrutide and a new lower-cost oral formulation called Foundayo targeting less affluent customers.
Beyond its current blockbuster portfolio, Eli Lilly is developing a small interfering RNA therapeutic targeting lipoprotein(a) for cardiovascular disease prevention, which analysts believe could become a billion-dollar revenue generator if approved. The article concludes that while Bristol Myers Squibb has potential, the premium valuation of Eli Lilly is justified by its long runway in the high-growth GLP-1 sector and its status as the market leader.
📈 FY 2025 revenue hit $65.2B, up 45% year-over-year.
💰 Net income reached $21B, more than doubling last year.
🚀 2026 revenue projected to exceed $88.6B driven by GLP-1.
💊 Foundayo pill targets less affluent customers directly.
🧬 Retatrutide triple-agonist approach expected to beat current results.
📈 Eli Lilly reported FY 2025 revenue of $65.2 billion, representing a 45% increase over the prior year.
💰 Net income for Eli Lilly reached approximately $21 billion in FY 2025, more than doubling the previous year's result.
📊 The company achieved a net margin of roughly 32% and maintained a debt-to-equity ratio of 1.6x as of December 2025.
🚀 Revenue is expected to grow over 30% in 2026, reaching an estimated $88.6 billion driven by GLP-1 demand.
💊 Net income for 2026 is projected to reach close to $31.4 billion as weight-loss and metabolic treatments scale.
🧬 The company's next weight-loss drug, Retatrutide, utilizes a triple-agonist approach expected to exceed current results.
💸 A new lower-cost GLP pill called Foundayo is being sold directly to consumers to target less affluent customers.
❤️ Eli Lilly is developing an siRNA therapeutic targeting lipoprotein(a) for cardiovascular disease prevention.
🏆 Analysts believe the lipoprotein(a) drug could generate over $1 billion in lifetime revenue if approved.
📉 Bristol Myers Squibb faces pricing pressure and patent expiration risks, contrasting with LLY's growth trajectory.
Bullish Signals
FY 2025 revenue hit $65.2B, up ~45% YoY.
Net income nearly doubled to ~$21B in FY 2025.
Achieved ~32% net margin, showing high profitability.
Drug approvalEarnings reportGuidance raisedAI-generated analysis
Eli Lilly (LLY) reported a robust 48% revenue growth in the second quarter of 2026, driven primarily by volume expansion rather than price increases. The company's core weight-loss portfolio remains highly profitable, with Mounjaro generating $9.9 billion and Zepbound adding $4.9 billion in the quarter. Despite a decline in realized prices due to market dynamics and international reimbursement changes, non-GAAP gross margins remained strong at 86.3%.
The company is expanding its product pipeline with the launch of Foundayo, a once-daily weight-loss pill that generated $98 million in first-quarter sales. Additionally, Lilly has secured full clinical data for retatrutide, a triple-action obesity drug, and plans to file for FDA approval in the first quarter of 2027. Management also raised its full-year 2026 revenue guidance to between $85 billion and $87 billion.
Despite the strong growth, LLY trades at a forward multiple of 30.94x earnings, which is significantly lower than its five-year average of 45.59x but still represents a premium to the broader healthcare sector. Analysts attribute this valuation compression to the company successfully growing earnings into the multiple, though risks remain regarding sustained volume growth and continued pricing pressure.
💊 Mounjaro ($9.9B) and Zepbound ($4.9B) dominate weight-loss market.
🚀 New pill Foundayo generated $98M in first quarter sales.
🔬 Retatrutide FDA filing planned for Q1 2027 with new data.
💰 Full-year 2026 guidance raised to $85-$87 billion range.
📈 Eli Lilly reported 48% revenue growth in Q2 2026, driven by a 60% jump in volume despite a 13% decline in realized prices.
💊 Mounjaro generated $9.9 billion and Zepbound added $4.9 billion in the second quarter, solidifying Lilly's dominance in the weight-loss market.
🚀 Foundayo, a new once-daily weight-loss pill, booked $98 million in sales during its first quarter of availability.
🔬 Lilly plans to file FDA data for retatrutide, a triple-action obesity drug, in Q1 2027 after completing clinical packages for sleep apnea and osteoarthritis.
💰 Management raised full-year 2026 revenue guidance to $85-$87 billion, up from the previous $82-$85 billion range.
📉 Non-GAAP gross margins held steady at 86.3% due to a richer product mix and cheaper production costs offsetting price declines.
🌍 International revenue surged 80% to $8.6 billion, with key medicines in immunology, oncology, and neuroscience growing 121%.
📊 The stock trades at 30.94x forward earnings, down from a five-year average of 45.59x, reflecting market pricing of growth sustainability.
⚠️ Management explicitly flags risks related to pricing pressure and the company's dependence on a few product classes for future revenue.
Bullish Signals
Revenue grew 48% in Q2 2026 with volume up 60%.
Mounjaro brought $9.9B; Zepbound added $4.9B in quarter.
Non-GAAP gross margin hit 86.3% despite price cuts.
Raised full-year 2026 guidance to $85-$87 billion.
Risk Factors
Realized prices fell 13% overall; 36% decline overseas due to Mounjaro reimbursement.
Management cites pricing pressure and product dependence as key risks.
Stock trades at 30.94x forward earnings, below 5-year average of 45.59x.
Bullish Signals
Revenue grew 48% in Q2 2026, with volume jumping 60% while realized prices fell only 13%, demonstrating strong demand elasticity.
Mounjaro brought in $9.9 billion and Zepbound added $4.9 billion in the quarter, confirming massive scale in the weight-loss category.
Non-GAAP gross margin reached 86.3% despite price cuts, aided by cheaper production costs and a richer product mix.
Foundayo generated $98 million in first-quarter sales, validating the commercial potential of the new once-daily oral formulation.
Management raised full-year 2026 revenue guidance to $85-$87 billion, signaling confidence in continued expansion.
Revenue outside the US rose 80% to $8.6 billion, diversifying the company's geographic exposure and reducing reliance on domestic markets.
Risk Factors
Realized prices fell 13% overall, with a 36% decline overseas due to Mounjaro joining China's national reimbursement list.
Management explicitly cites pricing pressure and dependence on a few product classes as key risks in its risk language.
The stock trades at 30.94x forward earnings, which is below the five-year average of 45.59x, suggesting the market may be discounting future growth sustainability.
Company updateDrug approvalProduct launchAI-generated analysis
Eli Lilly continues to solidify its dominant position in the global obesity drug market, particularly as rival Novo Nordisk faces investor skepticism regarding its growth strategy. In the burgeoning oral GLP-1 space, Lilly's new drug Foundayo is gaining significant traction, with CEO Dave Ricks reporting that one-third of new pill patients are already taking the company's medication. This momentum extends to the Medicare market, where 70% of seniors initiating GLP-1 therapy in July were prescribed Lilly's drugs, reinforcing its status as the dominant player in both injectable and oral segments.
Lilly maintains a substantial lead over Novo Nordisk in the overall U.S. GLP-1 space, holding approximately 61% market share in the second quarter compared to Novo's 39%. The company's primary driver remains Zepbound, an injectable drug with higher efficacy than initial Wegovy doses, which has helped secure its dominance despite Novo launching a higher-dose version of its own injection. Analysts highlight Lilly's 'tremendous commercial firepower' and global initiative as key advantages that allow it to maintain its leadership while competitors struggle to match its scale and manufacturing capacity.
Looking forward, Lilly is leveraging its advanced pipeline to extend its lead beyond current best-sellers. The company plans to seek approval for retatrutide, a triple-agonist drug showing superior weight loss in clinical trials, by the first quarter of 2027. Additionally, Lilly is developing a weekly injection targeting the amylin receptor, a pathway distinct from existing treatments, which analysts believe has significant potential given that many patients do not tolerate current GLP-1 drugs. These next-generation assets position Lilly to sustain growth even as patent expirations for competitors' core products approach.
Despite the competitive pressure, Lilly's strategy focuses on high-efficacy injectables and scalable oral options that offer convenience without compromising efficacy. While Novo Nordisk is pivoting toward a fragmented market with multiple new drug candidates to replace its mega-blockbuster franchise, Lilly is capitalizing on its established supply chain and commercial strength. The company's ability to manufacture small-molecule drugs like Foundayo more easily at scale than peptide-based competitors further enhances its long-term competitive moat in the obesity treatment landscape.
📈 Lilly holds 61% U.S. GLP-1 market share, ahead of Novo Nordisk.
💊 Foundayo captures one-third of new oral pill patients for Lilly.
👴 Lilly dominates Medicare obesity with 70% of senior GLP-1 prescriptions.
🚀 Zepbound drives injectable dominance with higher efficacy than original Wegovy.
🔬 Retatrutide expected Q1 2027 approval as superior triple-agonist weight loss drug.
📈 Eli Lilly holds a 61% market share in the U.S. GLP-1 space as of Q2, significantly ahead of rival Novo Nordisk's 39%.
💊 Foundayo is gaining rapid ground in the oral weight loss market, with one-third of new pill patients currently taking Lilly's drug.
👴 Lilly dominates the Medicare obesity market, capturing 70% of new GLP-1 prescriptions among seniors since coverage began in July.
🚀 Zepbound remains a key driver for Lilly, offering higher efficacy than original Wegovy doses and securing dominance in injectables.
🔬 Retatrutide is expected to receive approval in Q1 2027, representing a triple-agonist with superior weight loss results in trials.
💉 A new weekly injection targeting the amylin receptor is in development to address patients who do not tolerate current GLP-1s.
🏭 Foundayo's small-molecule structure allows for easier and more cost-effective manufacturing at scale compared to Novo's peptide drugs.
📊 Analyst Leerink Partners expects Foundayo to eventually dominate the global oral GLP-1 market due to Lilly's commercial firepower.
🔍 CagriSema from rival Novo showed mixed results in head-to-head trials, with lower doses showing less efficacy than Zepbound's active ingredient.
📈 Lilly's pipeline includes novel candidates designed to extend its lead beyond current best-sellers as patent expirations approach.
Bullish Signals
Holds 61% U.S. GLP-1 market share, outpacing rivals.
Bullish Signals
Eli Lilly holds a commanding 61% market share in the U.S. GLP-1 space, significantly outpacing rival Novo Nordisk which holds only 39%.
The company's new oral drug Foundayo is capturing one-third of all new GLP-1 pill patients, demonstrating rapid adoption and commercial success.
Lilly dominates the Medicare obesity market with 70% of new senior prescriptions following the start of coverage in July.
Zepbound continues to drive growth with higher efficacy than initial Wegovy doses, helping Lilly maintain its lead in the injectable segment.
Analysts highlight Lilly's 'tremendous commercial firepower' and global initiative as key advantages that sustain its leadership position.
The upcoming approval of retatrutide in Q1 2027 promises a triple-agonist drug with superior weight loss results compared to existing treatments.
Foundayo's small-molecule structure enables more cost-effective and scalable manufacturing than Novo's peptide-based competitors like Wegovy.
Guggenheim Capital has raised its price target for Eli Lilly (LLY) to $1,284 from $1,273 while maintaining a Buy rating, driven by strong demand for the company's weight-loss portfolio. The firm updated its financial model based on prescription trends and confirmed that Zepbound will return to CVS's formulary starting October 1, reinforcing expectations for sustained growth in the U.S. tirzepatide business which includes both Mounjaro and Zepbound.
Analysts at Guggenheim project continued expansion for Lilly's oral diabetes drug, Foundayo, with revenue estimates rising significantly from $1.2 billion in 2027 to $3.7 billion in 2028. This upward revision reflects an improving launch trajectory, while the firm's 2026 revenue estimate of $89.2 billion exceeds both Lilly's own guidance range and the broader Street consensus.
The bullish sentiment is echoed by other major institutions including Berenberg, which upgraded LLY to Buy with a $1,400 target citing strong investment returns, and BMO Capital, which reiterated an Outperform rating anticipating further revenue growth from Foundayo's approval in type 2 diabetes. The market appears confident that Lilly's metabolic health portfolio retains substantial room for growth despite recent valuation increases.
Beyond drug sales, Eli Lilly is strengthening its innovation pipeline through a strategic partnership with Twist Bioscience to enhance its AI and machine learning drug discovery platform, TuneLab. This collaboration aims to accelerate development by integrating antibody characterization data services, further solidifying the company's position in metabolic health research and potential future product launches.
Novo Nordisk's stock fell 7% following its capital markets day in London, where CEO Mike Doustdar guided the company to peer-average revenue growth through 2030. This guidance, which represents a slower expansion rate than historically expected for the Ozempic and Wegovy maker, triggered a multiple compression as investors repriced the stock from an outlier status to a standard industry performer.
The selloff was driven primarily by concerns over the impending loss of key patent exclusivity on semaglutide in the U.S. in 2032, a product that currently drives more than half of Novo Nordisk's annual sales. CEO Doustdar acknowledged the 'patent cliff' and noted that while almost every pharmaceutical company is now competing in the weight-loss market, the company plans to emerge as a larger, more diversified business beyond obesity and diabetes.
Unlike a broad sector repricing, rival GLP-1 competitor Eli Lilly saw its stock slip only 0.7%, indicating the negative sentiment was specific to Novo Nordisk's strategic pivot rather than a general downturn in the obesity drug market. The article notes that while Novo Nordisk is diversifying into blood disorders and cardiovascular disease, this strategy shift reverses previous focus sharpening, adding uncertainty to future growth projections.
Analysts suggest investors should treat the explicitly stated patent cliff and peer-average growth framing as confirmed risks, potentially moderating position sizes in the near term. The market is currently working to determine how much of the discount reflects pre-existing concerns versus new information from the strategy day, with traders watching for stabilization once materials are fully digested.
⚠️ Novo Nordisk patent expiry in 2032 threatens product accounting for over half of annual sales revenue.
🔄 Company pivoting strategy to diversify portfolio spanning blood disorders and liver disease by 2030.
📉 Novo Nordisk stock dropped 7% after guiding to peer-average revenue growth through 2030.
📉 Novo Nordisk stock dropped 7% to $40.26 after guiding to peer-average revenue growth through 2030, signaling a slowdown in the high-growth expectations previously priced into the Ozempic and Wegovy maker.
⚠️ CEO Mike Doustdar confirmed the U.S. patent on semaglutide expires in 2032, threatening the product that currently accounts for over half of the company's annual sales revenue.
🔄 The company is reversing its strategy to sharpen focus on obesity and diabetes, instead pivoting toward a diversified portfolio spanning blood disorders, liver disease, and cardiovascular conditions by 2030.
📊 Eli Lilly (LLY) stock slipped only 0.7% to $1,145.04, demonstrating that the market reaction was company-specific rather than a broad repricing of the entire GLP-1 obesity sector.
💰 Viking Therapeutics (VKTX) edged higher by 1%, as capital rotated toward next-generation obesity challengers while investors fled the incumbent Novo Nordisk.
📈 The SPDR S&P 500 ETF Trust (SPY) gained 0.6% while the Health Care Select Sector SPDR (XLV) slipped slightly, isolating the decline to Novo Nordisk's specific strategic guidance.
Risk Factors
Stock slipped 0.7% amid competitor pressure.
Remains unaffected by rival patent cliff fears.
Risk Factors
Eli Lilly stock slipped 0.7% as a direct competitor to Novo Nordisk, though the move was isolated and did not reflect a broad sector-wide repricing of obesity drug valuations.
The broader market context shows that while rivals like Viking Therapeutics are gaining attention as challengers, Eli Lilly remains largely unaffected by Novo Nordisk's specific patent cliff fears.
Eli Lilly (LLY) reported a blockbuster Q2 2026 quarter with revenue of $22.97 billion, representing a 47.7% year-over-year increase driven primarily by its incretin portfolio. The company's flagship drugs, Mounjaro and Zepbound, generated combined revenue of nearly $15 billion, with international sales surging following regulatory approvals in China. Management raised full-year 2026 revenue guidance to a range of $85 billion to $87 billion, citing continued momentum despite significant pricing headwinds.
The growth at Lilly is currently volume-driven rather than price-driven, as U.S. prices fell by 9% excluding rebate adjustments. To offset this pricing drag and expand its therapeutic reach, the company committed an additional $4.5 billion to Indiana manufacturing and absorbed $2.78 billion in IPR&D charges from recent acquisitions. The pipeline is expanding with a planned BLA filing for retatrutide in Q1 2027 covering obesity, sleep apnea, and knee OA pain.
Analysts remain optimistic about Lilly's long-term prospects, with forward EPS estimates for 2027 rising to $47.26 from $44.49 ninety days ago. The company is strategically positioning itself to build a portfolio that outlives any single molecule while navigating the transition from high-growth pricing power to volume-based expansion in the obesity market.
📈 Q2 2026 revenue hit $22.97B, up 47.7% YoY on Mounjaro and Zepbound.
🚀 FY2026 guidance raised to $85B-$87B driven by strong drug momentum.
💊 International Mounjaro sales surged 172% after China's NRDL listing.
📉 U.S. prices dropped 9%, shifting reliance to volume growth for expansion.
🏭 Lilly invested $4.5B in Indiana capacity and recorded $2.78B IPR&D charges.
📈 Eli Lilly booked $22.97 billion in Q2 2026 revenue, up 47.7% YoY, driven by Mounjaro and Zepbound.
💊 International Mounjaro sales jumped 172% following China's NRDL listing, expanding global market access.
📉 U.S. prices fell 9% excluding rebates, forcing the company to rely on volume growth for revenue expansion.
🚀 Management raised FY2026 revenue guidance to between $85B and $87B due to strong drug momentum.
🏭 Lilly committed another $4.5 billion to Indiana manufacturing capacity to support future demand.
💰 The company absorbed $2.78 billion in IPR&D charges from acquisitions of Orna, Ajax, Centessa, and Kelonia.
🔬 A retatrutide BLA filing is scheduled for Q1 2027 across obesity, sleep apnea, and knee OA indications.
📈 Forward EPS estimates for 2027 sit at $47.26, up from $44.49 ninety days ago as analysts revise higher.
Bullish Signals
Q2 2026 revenue beat $22.97B, up 47.7% YoY.
International Mounjaro sales surged 172% after China NRDL approval.
Raised full-year 2026 guidance to $85B-$87B.
Analysts raised 2027 EPS estimates to $47.26.
Risk Factors
U.S. pricing power eroding with 9% price decline excluding rebates.
Jim Cramer recently weighed in on healthcare stocks, specifically comparing Eli Lilly (LLY), Johnson & Johnson (JNJ), and Pfizer (PFE). While Cramer prefers J&J for its diversified portfolio and strong balance sheet, he acknowledged that LLY is a solid buy after a recent pullback, noting its key drug franchise potential. The article contextualizes these views against the backdrop of Q2 2026 earnings results from all four major players discussed.
Eli Lilly reported robust second-quarter performance with revenue jumping 48% to $23 billion and EPS rising 26% to $7.94. Growth was driven primarily by its weight-loss portfolio, with Mounjaro revenue surging 91% to $9.9 billion and US Zepbound increasing 44% to $4.9 billion. Consequently, the company raised its full-year 2026 revenue guidance to a range of $85-$87 billion.
Despite its strong growth, LLY trades at a forward P/E of 24.57, which is higher than J&J's 21.74 and Pfizer's 9.88. The primary risk identified for the stock is that high expectations are already priced in, making it vulnerable to any slowdown in demand, pricing pressure, or increased competition from its blockbuster weight-loss drugs.
Institutional positioning data shows LLY held by 152 hedge funds in Q2, an increase from 132 in Q1. Short interest remains low at roughly 0.7%-0.8% of float. The article concludes that while LLY offers the strongest growth profile among the group, investors must weigh this against its valuation premium compared to more diversified or value-oriented peers like J&J and Pfizer.
📈 LLY Q2 revenue hit $23B, up 48% year-over-year.
💊 Mounjaro revenue surged 91% to $9.9 billion.
📈 Raised 2026 guidance to $85-$87 billion range.
💰 EPS rose 26% to $7.94, non-GAAP up 33%.
⚠️ Faces risks from high valuation and demand slowdowns.
📈 Eli Lilly reported Q2 revenue of $23 billion, a 48% increase year-over-year.
💊 Mounjaro revenue surged 91% to $9.9 billion, while US Zepbound grew 44% to $4.9 billion.
📈 The company raised its 2026 revenue guidance to $85-$87 billion.
💰 Reported EPS increased 26% to $7.94, with non-GAAP EPS rising 33% to $8.38.
📊 LLY trades at a forward P/E of 24.57, higher than peers J&J (21.74) and Pfizer (9.88).
🏦 Institutional ownership increased, with 152 hedge funds holding the stock in Q2.
⚠️ The stock faces risks from high valuation expectations and potential demand slowdowns.
📉 Short interest is low at approximately 0.7%-0.8% of the float.
Bullish Signals
Revenue jumped 48% to $23B in Q2.
Mounjaro revenue rose 91% to $9.9B.
Raised 2026 guidance to $85-$87B.
EPS grew 26% to $7.94.
Hedge fund holders increased to 152.
Risk Factors
Forward P/E of 24.57 is significantly higher than peers.
High expectations leave stock vulnerable to demand slowdowns.
Reliance on Mounjaro/Zepbound exposes growth to competition.
Bullish Signals
Eli Lilly achieved a massive 48% revenue jump to $23 billion in Q2, driven by explosive growth in its weight-loss franchise.
Mounjaro revenue increased 91% to $9.9 billion and US Zepbound grew 44% to $4.9 billion, validating the core investment thesis.
The company successfully raised its 2026 revenue guidance to $85-$87 billion, demonstrating confidence in future demand.
EPS growth was strong with reported earnings up 26% to $7.94 and non-GAAP earnings up 33% to $8.38.
Institutional interest is growing, evidenced by a rise in hedge fund holders from 132 to 152 in the second quarter.
Risk Factors
The stock trades at a forward P/E of 24.57, which is significantly higher than peers like J&J (21.74) and Pfizer (9.88), indicating high valuation risk.
High expectations are already reflected in the current price, leaving the stock vulnerable to any slowdown in demand or pricing pressure.
Continued heavy reliance on Mounjaro and Zepbound for growth exposes the company to risks from competition and potential market saturation.
Eli Lilly and Company (NYSE: LLY) received FDA approval for its diabetes drug Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes who face a high risk of cardiovascular events. This regulatory decision expands the drug's clinical profile beyond glycemic control, allowing physicians to prescribe it based on cardiovascular benefits in addition to diabetes management.
The approval is supported by robust clinical evidence from a large head-to-head study where Mounjaro demonstrated superior efficacy compared to Lilly's own older diabetes medicine, Trulicity. Specifically, the study found that Mounjaro reduced the risk of major adverse cardiovascular events by 8% more than Trulicity, providing a compelling argument for physicians treating high-risk patients.
Commercially, Mounjaro is already experiencing substantial momentum with second-quarter sales increasing 91% year over year to $9.94 billion. While Lilly has not disclosed specific revenue expectations from this new indication, the expanded label strengthens the drug's position in a competitive market where cardiovascular benefits are increasingly valued, potentially reinforcing growth within its eligible patient population.
This development aligns with Lilly's broader strategy of extending its GLP-1 medicines into non-diabetic conditions and validating their utility in cardiovascular care. The company is also exploring these drugs for liver disorders and other metabolic conditions, using the Mounjaro approval as tangible proof that their platform can yield regulatory success beyond original indications.
📈 FDA approved Mounjaro to reduce heart attack or stroke risk in high-risk adults with type 2 diabetes.
💰 Mounjaro sales surged 91% year over year to $9.94 billion in the second quarter.
🏥 New indication allows prescribing Mounjaro for cardiovascular risk reduction alongside diabetes control.
🚀 Lilly is testing its GLP-1 medicines in conditions ranging from cardiovascular disease to liver disorders.
📈 FDA approved Mounjaro to reduce heart attack or stroke risk in high-risk adults with type 2 diabetes.
🔬 Clinical study showed Mounjaro reduced major adverse cardiovascular events by 8% more than Lilly's Trulicity.
💰 Mounjaro sales surged 91% year over year to $9.94 billion in the second quarter.
🏥 The new indication allows physicians to prescribe Mounjaro for cardiovascular risk reduction alongside diabetes control.
🚀 Lilly is testing its GLP-1 medicines in conditions ranging from cardiovascular disease to liver disorders.
⚖️ Novo Nordisk previously secured similar cardiovascular-risk approvals for Wegovy and Rybelsus.
📊 The approval targets a specific high-risk population rather than all Mounjaro patients.
Bullish Signals
FDA approved Mounjaro to reduce heart attack/stroke risk in high-risk T2D patients.
Bullish Signals
FDA approved Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes who face a high risk of cardiovascular events.
Clinical evidence demonstrated that Mounjaro outperformed Trulicity, reducing the risk of major adverse cardiovascular events by 8% more than the competitor drug.
Mounjaro sales increased 91% year over year to $9.94 billion during the second quarter, supported by higher volumes across global markets.
The expanded indication strengthens Lilly's strategy of extending its metabolic medicines into cardiovascular care and validates their platform for regulatory approvals beyond original indications.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)